UFP Technologies Q3 2026 Earnings: Organic Growth and Margin Expansion Lift Profit

UFP Technologies (Nasdaq: UFPT) reported Q3 2026 net sales of $172.4 million, up 11.6% year over year, while GAAP diluted EPS rose to $2.64 from $2.11. For the quarter ended September 30, 2026, organic growth accounted for most of the revenue increase, while a higher gross margin and lower interest expense helped net income grow faster than sales.

Core Earnings Results

Organic sales increased 11.1%, compared with total sales growth of 11.6%. Acquired operations contributed $0.7 million of quarterly sales in the company’s organic growth reconciliation, indicating that existing operations generated nearly all of the increase.

Gross profit grew faster than revenue as gross margin expanded to 29.4%. GAAP operating income rose 18.1% to $27.6 million, while adjusted operating income increased 14.5% to $30.1 million. Net income advanced 25.8%, supported in part by lower interest expense.

Adjusted results exclude items including intangible asset amortization, acquisition costs, changes in contingent consideration and gains or losses on asset disposals.

Business and Product Performance

MedTech sales increased 12.5% in Q3, with management attributing the result to broad-based demand across the portfolio. For the first nine months of 2026, MedTech sales and combined sales to the company’s five largest MedTech customers each grew 11.7%.

Management reported progress in scaling new programs in the Dominican Republic and improving margins in UFP’s legacy operations. The company also said its 2025 investment in TPI exceeded expectations and established an initial position in injection molding, a capability it intends to expand.

AJR improved year over year in both the United States and the Dominican Republic. However, scheduled program transfers to the Dominican Republic and related margin improvements remained behind plan. UFP also invested in additional capacity at DAS Medical to support management’s double-digit growth objective for that business.

Gross Margin Expansion Outran SG&A Pressure

The 170-basis-point increase in gross margin was the quarter’s main profitability driver. It more than offset SG&A growth of 21.4%, which exceeded the 11.6% increase in sales. SG&A rose to 13.4% of revenue from 12.3%, while adjusted SG&A increased to 12.0% of revenue from 10.7%.

As a result, GAAP operating margin still improved to approximately 16.0% from 15.1%. Net income grew even faster than operating income because net interest expense declined to $1.5 million from $2.4 million. The quarter therefore showed better production-level profitability, but also higher corporate and operating expenses that limited some of the resulting operating leverage.

Debt Fell While Receivables and Inventory Increased

Cash and cash equivalents were largely unchanged at $20.6 million on September 30, compared with $20.3 million at the end of 2025. Reported current and long-term debt totaled $96.0 million, down approximately $39.5 million from $135.5 million at year-end.

Receivables increased to $97.2 million from $82.9 million, while inventories rose to $98.1 million from $86.9 million. The release did not provide operating or free cash flow, so the effect of these higher working-capital balances on cash conversion cannot be quantified from the supplied figures.

Recent Insider Transactions

The supplied insider data show 12 purchase transactions covering 16,202 shares and nine sale transactions covering 44,094 shares during the latest six-month period. That produced net sales of 27,892 shares, equivalent to a net change of negative 8.60%; total insider holdings were listed at approximately 295,420 shares.

The 10 most recent reported transactions included eight sales and two exercises or conversions of derivative securities. These transactions are presented objectively and do not, by themselves, establish insiders’ views about the company’s outlook.

Bailly’s two sales were reported as indirect transactions; the other eight entries were direct. The derivative exercise and conversion entries should not be treated as open-market purchases.

Risks Investors Need to Watch

• SG&A is rising faster than revenue. Continued expense growth at the Q3 rate could offset further gross-margin gains and constrain operating leverage.
• Dominican Republic execution remains behind plan. Delayed program transfers and slower margin improvement at AJR could postpone anticipated operational benefits.
• Large-customer dependence remains material. The company depends on substantial purchases from its largest customers, exposing revenue to changes in order volumes, sourcing decisions and contract terms.
• Working-capital balances have increased. Higher receivables and inventories may require additional cash to support growth, while the release did not provide cash flow data to assess conversion during the quarter.

Summary

UFP Technologies’ Q3 2026 growth was predominantly organic, led by higher MedTech sales, while gross-margin expansion and lower interest expense helped earnings grow faster than revenue. The main follow-up issues are whether the company can control SG&A, complete delayed Dominican Republic program transfers and convert higher receivables and inventory into cash while continuing to reduce debt.